Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Inks Blue Cross and Blue Shield Contract

NEW YORK (GenomeWeb News) – Transgenomic said today that it has expanded a national contractual agreement with the Blue Cross and Blue Shield Association.

The Omaha, Neb.-based molecular diagnostics and pharmacogenomics services firm said in a filing with the US Securities and Exchange Commission that the new agreement has a term of five years. Under the contract, Blue Plans affiliates have access to "competitive pricing" for Transgenomic's tests and services.

The firm didn't provide any additional details of the contract.

Transgenomic offers genetic analysis kits for a variety of mutations, including BRAF, KRAS, and NRAS. The kits feature the company's Ice-Cold-PCR technology.

in Friday afternoon trade on the OTC Market shares of Transgenomic were up 14 percent at $.48.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.